Data & Analytics
In this webcast, TrialCard VP of analytic services Paul LeVine and senior analytic consultant Robert Leedom underscore how affordability programs provide the ideal venue for focusing on adherence issues.
Jawbone data shows that people mentioning Pokémon Go in their comments have been walking 62.5% more than usual.
Mergers and acquisitions targeting digital and data capabilities increased 60% to $1 billion in the first half of 2016.
IBM to help analyze data about the spread of Zika; Grassley to investigate Part D program; Lilly CEO to retire
Spending on CME rose in 2015; the FDA approves Valeant's Relistor; the Justice Department aims to block insurer merger
Healthcare marketing is evolving more rapidly than ever before — and not surprisingly, the demand for smarter media campaign measurement is increasing as a result.
A new analysis suggests that $20 industry-sponsored meals may sway docs' prescribing habits.
The ability to pair data with a story or a human emotion is often easier for women.
Despite the increasing importance of the CIO post, top technology professionals still find it hard to break into the uppermost ranks at life-sciences companies.
Only 55% of the surveyed pharmaceutical executives said they are adopting digital as a key strategy in R&D.
BIO report finds success rate in Phase-I is 10%; Dunsire departs Forum after failed trials; the FDA issues two warning letters
Two recent polls paint a complicated picture of the public's opinion of the pharma industry.
Keytruda's survival benefit is reinforced by new study; drugmakers reference patient-assistance programs in debate over drug prices; China cuts drug prices
A 69% majority of healthcare organizations said they believe their industry is more vulnerable to data breaches than other business sectors.
Learn more about the top therapeutic categories by sales, top companies by revenue, top drugs by sales, and more.
"Social can enable a better starting point to yield better questions and thus make surveys less in number yet greater in value."
The move away from a fee-for-service reimbursement model and the arrival of promising new technology have created demand for big data in healthcare.
2015 marks the second straight double digit increase in spend, which was driven by recent launches and specialty brands.
Analyst survey says docs want outcomes benefit from PCSK9s; Allergan licenses early-stage Alzheimer's drugs; Pfizer and IBM partner in Parkinson's disease
The results of a failed trial for Lilly's CEPT inhibitor has analysts saying there is little hope for Merck's drug in the same class.
Given the value of its data and its relatively backward security measures, the healthcare industry has become a prime target for hackers. But industry experts say changes are afoot.
Time is everything, yet no one has enough of it. But especially in healthcare marketing, time and timing win customers.
Consumers are more likely to use health information websites they find easier to navigate than those perceived as trustworthy, like government sites, new research shows.
Analysis questions Addyi's effectiveness; Horizon is subpoenaed about its patient assistance programs; AstraZeneca sells non-U.S. rights to constipation drug
With these changes coming to healthcare from precision medicine, it may no longer be acceptable to do generic or broad marketing campaigns in hopes of catching the small group of people who may benefit from a device or treatment.
The agency announced a partnership with Vencore Health Analytics to help pair rare disease patients with drugmakers.
Despite conventional wisdom that the 23andMe business breakthrough is the direct-to-consumer model, it's also the consolidation of genetic testing, diagnosis and drug development that has the potential to change the industry.
Healthcare spending rose in 2014; Publicis reorganizes its agency network; proposed New Jersey bill would punish drugmakers that move abroad
Healthcare may seem to have been unscarred by the ongoing rash of high-profile cyber-attacks, at least compared with retail and financial organizations. But to hear security pros tell it, the industry is increasingly finding itself as much of a target as companies in other sectors—if not more of one. Karen Epper Hoffman surveys the potential damage
Specialty medicines will keep drug spend trending upward through the next five years.
- Shire taps Jennifer Aniston for awareness campaign as it enters the eye care market
- The co-pay card debate simmers, as payers push back
- Five things for pharma marketers to know: Tuesday, August 23, 2016
- Drugmakers revive R&D focus on long stagnant women's health market
- Five things for pharma marketers to know: Wednesday, August 24, 2016
- Boehringer Ingelheim launches gamified support program
- Leadership Exchange: Engaging the Millennial Doctor
- Klick opens NY office with slew of agency 'rock stars'
- Omnicom merges AgencyRx, Flashpoint and three other agencies to form DDB Health
- No free lunch for docs: Sponsored meals linked to more prescriptions
- Five things for pharma marketers to know: Tuesday, August 30, 2016
- Infographic: How physicians share online info with patients and other docs
- Diabetes marketers turn to big data, gaming to improve outcomes
- Health exchanges, Obama administration challenged by recent insurer exits
- Five things for pharma marketers to know: Monday, August 29, 2016